Michael Demurjian
Chief Executive Officer bei Aspargo Laboratories, Inc.
Profil
Michael Demurjian is the founder of Tyme Technologies, Inc. (founded in 2011), Mikronite Technologies Group, Inc. (founded in 1993), and Luminant Biosciences LLC (founded in 2011).
He held various titles at Tyme Technologies, Inc. and Mikronite Technologies Group, Inc. He is currently the Chairman & Chief Executive Officer at Aspargo Laboratories, Inc. and the Chief Operating Officer at Tyme, Inc. Mr. Demurjian received his undergraduate degree from New York University in 1986.
Aktive Positionen von Michael Demurjian
| Unternehmen | Position | Beginn |
|---|---|---|
Tyme, Inc.
 Tyme, Inc. BiotechnologyHealth Technology Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a private company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015. | Chief Operating Officer | - |
Aspargo Laboratories, Inc.
 Aspargo Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company, which focuses on developing an oral spray formulation of sildenafil. Its products include Sildenafil Oral Spray, an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push of the pump or via an individual single liquid unit dispensing 100 mg per unit. The company was founded in 2019 and is headquartered in Englewood Cliffs, NJ. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Michael Demurjian
| Unternehmen | Position | Ende |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Founder | 15.03.2019 |
Mikronite Technologies Group, Inc.
 Mikronite Technologies Group, Inc. Auto Parts: OEMProducer Manufacturing Mikronite Technologies Group, Inc. provides material surfacing technologies. The company was founded by Michael Demurjian and Steve Hoffman and is headquartered in Eatontown, NJ. | Founder | 01.01.2007 |
| Luminant Biosciences LLC | Founder | - |
Ausbildung von Michael Demurjian
| New York University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Mikronite Technologies Group, Inc.
Mikronite Technologies Group, Inc. Auto Parts: OEMProducer Manufacturing Mikronite Technologies Group, Inc. provides material surfacing technologies. The company was founded by Michael Demurjian and Steve Hoffman and is headquartered in Eatontown, NJ. | Producer Manufacturing |
Tyme, Inc.
Tyme, Inc. BiotechnologyHealth Technology Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a private company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015. | Health Technology |
| Luminant Biosciences LLC | |
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company, which focuses on developing an oral spray formulation of sildenafil. Its products include Sildenafil Oral Spray, an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push of the pump or via an individual single liquid unit dispensing 100 mg per unit. The company was founded in 2019 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
